RET and non-small cell lung carcinoma: A previous work at the phase I/II trial of selpercatinib (LOXO-292) documented a similar rapid clinical response in a patient with a RET-fusion-positive NSCLC with leptomeningeal metastasis, further supporting our findings [14].